Skip to main content
PMC home page
The Journal of Cell Biology logoLink to The Journal of Cell Biology
. 1990 Jan 1;110(1):155–163. doi: 10.1083/jcb.110.1.155

The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator

PMCID: PMC2115987  PMID: 2104856

Abstract

The interactions between exogenously added tissue-type plasminogen activator (t-PA) and the active form of type 1 plasminogen activator inhibitor (PAI-1) produced by and present in cultured human umbilical vein endothelial cells (HUVECs) were investigated. Immunoblotting analysis of the conditioned media obtained from monolayers of HUVECs treated with increasing concentrations of t-PA (less than or equal to 10 micrograms/ml) revealed a dose-dependent formation of both t-PA/PAI- 1 complexes, and of a 42,000-Mr cleaved or modified form of the inhibitor. Immunoradiometric assays indicated that t-PA treatment resulted in a fourfold increase in PAI-1 antigen present in the conditioned media. This increase did not result from the release of PAI- 1 from intracellular stores, but rather reflected a t-PA-dependent decrease in the PAI-1 content of the Triton X-100 insoluble extracellular matrix (ECM). Although the rate of t-PA-mediated release of PAI-1 was increased by the removal of the monolayer, similar quantities of PAI-1 were removed in the presence or absence of the cells. These results suggest that the cells only represent a semipermeable barrier between ECM-associated PAI-1 and exogenous t-PA. Treatment of HUVECs with t-PA (1 microgram/ml, 2 h) to deplete the ECM of PAI-1 did not affect the subsequent rate of PAI-1 production and deposition into the ECM. Immunogold electron microscopy of HUVECs not only confirmed the location of PAI-1 primarily in the region between the culture substratum and ventral cell surface but failed to demonstrate significant (less than 1%) PAI-1 on the cell surface. Thus, the majority of PAI-1 associated with cultured HUVEC monolayers is present under the cells in the ECM and is accessible to solution-phase t-PA.

Full Text

The Full Text of this article is available as a PDF (2.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avnur Z., Geiger B. Substrate-attached membranes of cultured cells isolation and characterization of ventral cell membranes and the associated cytoskeleton. J Mol Biol. 1981 Dec 5;153(2):361–379. doi: 10.1016/0022-2836(81)90283-7. [DOI] [PubMed] [Google Scholar]
  2. Bachmann F., Kruithof I. E. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost. 1984 Jan;10(1):6–17. doi: 10.1055/s-2007-1004403. [DOI] [PubMed] [Google Scholar]
  3. Barnathan E. S., Kuo A., Van der Keyl H., McCrae K. R., Larsen G. R., Cines D. B. Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. J Biol Chem. 1988 Jun 5;263(16):7792–7799. [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  5. Carter W. G., Hakomori S. A new cell surface, detergent-insoluble glycoprotein matrix of human and hamster fibroblasts. The role of disulfide bonds in stabilization of the matrix. J Biol Chem. 1981 Jul 10;256(13):6953–6960. [PubMed] [Google Scholar]
  6. Colucci M., Paramo J. A., Collen D. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo. J Lab Clin Med. 1986 Jul;108(1):53–59. [PubMed] [Google Scholar]
  7. Declerck P. J., De Mol M., Alessi M. C., Baudner S., Pâques E. P., Preissner K. T., Müller-Berghaus G., Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988 Oct 25;263(30):15454–15461. [PubMed] [Google Scholar]
  8. Del Vecchio P. J., Siflinger-Birnboim A., Shepard J. M., Bizios R., Cooper J. A., Malik A. B. Endothelial monolayer permeability to macromolecules. Fed Proc. 1987 Jun;46(8):2511–2515. [PubMed] [Google Scholar]
  9. Erickson L. A., Hekman C. M., Loskutoff D. J. Denaturant-induced stimulation of the beta-migrating plasminogen activator inhibitor in endothelial cells and serum. Blood. 1986 Dec;68(6):1298–1305. [PubMed] [Google Scholar]
  10. Erickson L. A., Schleef R. R., Ny T., Loskutoff D. J. The fibrinolytic system of the vascular wall. Clin Haematol. 1985 Jun;14(2):513–530. [PubMed] [Google Scholar]
  11. Furie M. B., Cramer E. B., Naprstek B. L., Silverstein S. C. Cultured endothelial cell monolayers that restrict the transendothelial passage of macromolecules and electrical current. J Cell Biol. 1984 Mar;98(3):1033–1041. doi: 10.1083/jcb.98.3.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hajjar K. A., Hamel N. M., Harpel P. C., Nachman R. L. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest. 1987 Dec;80(6):1712–1719. doi: 10.1172/JCI113262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hekman C. M., Loskutoff D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985 Sep 25;260(21):11581–11587. [PubMed] [Google Scholar]
  14. Hekman C. M., Loskutoff D. J. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys. 1988 Apr;262(1):199–210. doi: 10.1016/0003-9861(88)90182-8. [DOI] [PubMed] [Google Scholar]
  15. Hormia M., Lehto V. P., Virtanen I. Factor VIII-related antigen. A pericellular matrix component of cultured human endothelial cells. Exp Cell Res. 1983 Dec;149(2):483–497. doi: 10.1016/0014-4827(83)90360-9. [DOI] [PubMed] [Google Scholar]
  16. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912–2919. [PubMed] [Google Scholar]
  17. Huang A. J., Furie M. B., Nicholson S. C., Fischbarg J., Liebovitch L. S., Silverstein S. C. Effects of human neutrophil chemotaxis across human endothelial cell monolayers on the permeability of these monolayers to ions and macromolecules. J Cell Physiol. 1988 Jun;135(3):355–366. doi: 10.1002/jcp.1041350302. [DOI] [PubMed] [Google Scholar]
  18. Jaffe E. A., Minick C. R., Adelman B., Becker C. G., Nachman R. Synthesis of basement membrane collagen by cultured human endothelial cells. J Exp Med. 1976 Jul 1;144(1):209–225. doi: 10.1084/jem.144.1.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Knudsen B. S., Harpel P. C., Nachman R. L. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest. 1987 Oct;80(4):1082–1089. doi: 10.1172/JCI113164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Knudsen B. S., Nachman R. L. Matrix plasminogen activator inhibitor. Modulation of the extracellular proteolytic environment. J Biol Chem. 1988 Jul 5;263(19):9476–9481. [PubMed] [Google Scholar]
  21. Knudsen B. S., Silverstein R. L., Leung L. L., Harpel P. C., Nachman R. L. Binding of plasminogen to extracellular matrix. J Biol Chem. 1986 Aug 15;261(23):10765–10771. [PubMed] [Google Scholar]
  22. Kooistra T., Sprengers E. D., van Hinsbergh V. W. Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. Biochem J. 1986 Nov 1;239(3):497–503. doi: 10.1042/bj2390497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  24. Laiho M., Saksela O., Andreasen P. A., Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol. 1986 Dec;103(6 Pt 1):2403–2410. doi: 10.1083/jcb.103.6.2403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Levin E. G. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood. 1986 May;67(5):1309–1313. [PubMed] [Google Scholar]
  26. Levin E. G., Santell L. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biol. 1987 Dec;105(6 Pt 1):2543–2549. doi: 10.1083/jcb.105.6.2543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Loscalzo J., Braunwald E. Tissue plasminogen activator. N Engl J Med. 1988 Oct 6;319(14):925–931. doi: 10.1056/NEJM198810063191407. [DOI] [PubMed] [Google Scholar]
  28. Loskutoff D. J., Sawdey M., Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87–115. [PubMed] [Google Scholar]
  29. Lucore C. L., Sobel B. E. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988 Mar;77(3):660–669. doi: 10.1161/01.cir.77.3.660. [DOI] [PubMed] [Google Scholar]
  30. Mimuro J., Loskutoff D. J. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem. 1989 Mar 25;264(9):5058–5063. [PubMed] [Google Scholar]
  31. Mimuro J., Loskutoff D. J. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem. 1989 Jan 15;264(2):936–939. [PubMed] [Google Scholar]
  32. Mimuro J., Schleef R. R., Loskutoff D. J. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood. 1987 Sep;70(3):721–728. [PubMed] [Google Scholar]
  33. Ny T., Sawdey M., Lawrence D., Millan J. L., Loskutoff D. J. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6776–6780. doi: 10.1073/pnas.83.18.6776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pannekoek H., Veerman H., Lambers H., Diergaarde P., Verweij C. L., van Zonneveld A. J., van Mourik J. A. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J. 1986 Oct;5(10):2539–2544. doi: 10.1002/j.1460-2075.1986.tb04532.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pöllänen J., Saksela O., Salonen E. M., Andreasen P., Nielsen L., Danø K., Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol. 1987 Apr;104(4):1085–1096. doi: 10.1083/jcb.104.4.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rheinwald J. G., Jorgensen J. L., Hahn W. C., Terpstra A. J., O'Connell T. M., Plummer K. K. Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol. 1987 Feb;104(2):263–275. doi: 10.1083/jcb.104.2.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sakata Y., Okada M., Noro A., Matsuda M. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells. J Biol Chem. 1988 Feb 5;263(4):1960–1969. [PubMed] [Google Scholar]
  38. Schleef R. R., Bevilacqua M. P., Sawdey M., Gimbrone M. A., Jr, Loskutoff D. J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem. 1988 Apr 25;263(12):5797–5803. [PubMed] [Google Scholar]
  39. Schleef R. R., Sinha M., Loskutoff D. J. Characterization of two monoclonal antibodies against human tissue-type plasminogen activator. Thromb Haemost. 1985 Apr 22;53(2):170–175. [PubMed] [Google Scholar]
  40. Schleef R. R., Wagner N. V., Loskutoff D. J. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells. J Cell Physiol. 1988 Feb;134(2):269–274. doi: 10.1002/jcp.1041340213. [DOI] [PubMed] [Google Scholar]
  41. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
  42. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Vassalli J. D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985 Jan;100(1):86–92. doi: 10.1083/jcb.100.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wiman B., Lindahl T., Almqvist A. Evidence for a discrete binding protein of plasminogen activator inhibitor in plasma. Thromb Haemost. 1988 Jun 16;59(3):392–395. [PubMed] [Google Scholar]
  45. van Mourik J. A., Lawrence D. A., Loskutoff D. J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem. 1984 Dec 10;259(23):14914–14921. [PubMed] [Google Scholar]

Articles from The Journal of Cell Biology are provided here courtesy of The Rockefeller University Press

RESOURCES